Achieve Life Sciences, Inc. (ACHV)
- Previous Close
5.27 - Open
5.24 - Bid 5.11 x 200
- Ask 5.14 x 100
- Day's Range
5.11 - 5.26 - 52 Week Range
3.03 - 5.98 - Volume
57,504 - Avg. Volume
123,654 - Market Cap (intraday)
175.827M - Beta (5Y Monthly) 1.57
- PE Ratio (TTM)
-- - EPS (TTM)
-1.07 - Earnings Date Nov 7, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.00
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
www.achievelifesciences.comRecent News: ACHV
View More
Performance Overview: ACHV
Trailing total returns as of 10/9/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACHV
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACHV
View MoreValuation Measures
Market Cap
175.83M
Enterprise Value
132.16M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.16
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-33.84%
Return on Equity (ttm)
-105.95%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-27.54M
Diluted EPS (ttm)
-1.07
Balance Sheet and Cash Flow
Total Cash (mrq)
61.31M
Total Debt/Equity (mrq)
41.73%
Levered Free Cash Flow (ttm)
-12.16M
Research Analysis: ACHV
View MoreCompany Insights: ACHV
ACHV does not have Company Insights